Global HIV Disease Coverage Forecast and Market 2018-2024: B/F/TAF will Drive Significant Revenue Growth Due to its Attractive Combination of an INSTI and a Preferred Backbone

Dublin, May 11, 2018 (GLOBE NEWSWIRE) -- The "HIV Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

• B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
• TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
• HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
• Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
• B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.

Key Topics Covered:

Forecast: HIV

• Overview
• Executive Summary
• Market Dynamics
• Forecast And Future Trends
• Market Definition And Methodology
• Primary Research Methodology
• Bibliography
• Product Profile: Atripla
• Product Profile (Late Stage): B/F/Taf
• Product Profile: Complera
• Product Profile (Late Stage): Dor/3Tc/Tdf
• Product Profile: Descovy
• Product Profile: Genvoya
• Product Profile: Isentress
• Product Profile: Juluca
• Product Profile: Odefsey
• Product Profile: Prezista Franchise
• Product Profile: Reyataz Franchise
• Product Profile: Stribild
• Product Profile: Symtuza
• Product Profile: Tivicay
• Product Profile (Late Stage): Tivicay/Epivir
• Product Profile: Triumeq
• Product Profile: Truvada
• Product Profile (Late Stage): Cabotegravir/Rilpivirine
• Product Profile (Late Stage): Fostemsavir

Treatment: HIV

• Overview
• Primary Research Methodology
• Disease Definition And Diagnosis
• Patient Segmentation
• Current Treatment Options
• Treatment Guidelines
• Prescribing Trends
• Unmet Needs In HIV
• Impact Of Generics

Epidemiology: HIV

• Overview
• Executive Summary
• Disease Background
• Sources And Methodology
• Forecast: HIV
• Epidemiologist Insight
• Strengths And Limitations
• Appendix: Additional Sources
• Bibliography

Marketed Drugs: HIV

• Overview
• Executive Summary
• Product Overview
• Product Profile: Atripla
• Product Profile: Complera
• Product Profile: Descovy
• Product Profile: Genvoya
• Product Profile: Isentress
• Product Profile: Juluca
• Product Profile: Odefsey
• Product Profile: Prezista Franchise
• Product Profile: Reyataz Franchise
• Product Profile: Stribild
• Product Profile: Symtuza
• Product Profile: Tivicay
• Product Profile: Triumeq
• Product Profile: Truvada

Pipeline: HIV

• Overview
• Executive Summary
• Clinical Pipeline Overview
• Product Profile (Late Stage): B/F/Taf
• Product Profile (Late Stage): Dor/3Tc/Tdf
• Product Profile (Late Stage): Tivicay/Epivir
• Product Profile (Late Stage): Cabotegravir/Rilpivirine
• Product Profile (Late Stage): Fostemsavir

For more information about this report visit https://www.researchandmarkets.com/research/4zcdv3/global_hiv?w=12

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs